# Mark G. Kris

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mark-g-kris/

## Facts

| Field | Value |
| --- | --- |
| Citations | 102,485 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 149 |
| i10-index | 539 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5039791495 |
| ORCID iD | 0000-0002-7317-5341 |
| Works | 1,388 |

## Researcher papers

Showing 12 of 28.

- [EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib](https://scholariq.org/papers/egf-receptor-gene-mutations-are-common-in-lung-cancers-from-never-smokers-and/)
- [Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain](https://scholariq.org/papers/acquired-resistance-of-lung-adenocarcinomas-to-gefitinib-or-erlotinib-is/)
- [Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial](https://scholariq.org/papers/symptom-monitoring-with-patient-reported-outcomes-during-routine-cancer/)
- [Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer](https://scholariq.org/papers/efficacy-of-gefitinib-an-inhibitor-of-the-epidermal-growth-factor-receptor/)
- [Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers](https://scholariq.org/papers/analysis-of-tumor-specimens-at-the-time-of-acquired-resistance-to-egfr-tki/)
- [Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment](https://scholariq.org/papers/overall-survival-results-of-a-trial-assessing-patient-reported-outcomes-for/)
- [Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs](https://scholariq.org/papers/using-multiplexed-assays-of-oncogenic-drivers-in-lung-cancers-to-select-targeted/)
- [KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib](https://scholariq.org/papers/kras-mutations-and-primary-resistance-of-lung-adenocarcinomas-to-gefitinib-or/)
- [TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/tribute-a-phase-iii-trial-of-erlotinib-hydrochloride-osi-774-combined-with/)
- [Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing](https://scholariq.org/papers/molecular-determinants-of-response-to-anti-programmed-cell-death-pd-1-and-anti/)
- [Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study](https://scholariq.org/papers/gene-expression-based-survival-prediction-in-lung-adenocarcinoma-a-multi-site/)
- [Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis](https://scholariq.org/papers/serpins-promote-cancer-cell-survival-and-vascular-co-option-in-brain-metastasis/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.